Classical vs reverse pharmacology in drug discovery
2001; Wiley; Volume: 88; Issue: s2 Linguagem: Inglês
10.1111/j.1464-410x.2001.00112.x
ISSN1464-410X
Autores Tópico(s)Pharmaceutical Economics and Policy
ResumoBJU InternationalVolume 88, Issue s2 p. 7-10 Classical vs reverse pharmacology in drug discovery T. Takenaka, T. Takenaka Yamanouchi Pharmaceutical Co., Ltd, Tokyo, JapanSearch for more papers by this author T. Takenaka, T. Takenaka Yamanouchi Pharmaceutical Co., Ltd, Tokyo, JapanSearch for more papers by this author First published: 18 July 2008 https://doi.org/10.1111/j.1464-410X.2001.00112.xCitations: 35 T. Takenaka, PhD, President and CEO, Yamanouchi Pharmaceutical Co., Ltd, 3-1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 10 3–8411, Japan. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume88, Issues2September 2001Pages 7-10 RelatedInformation
Referência(s)